# An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

> **NCT01945710** · PHASE1 · COMPLETED · sponsor: **Eisai Limited** · enrollment: 62 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Eribulin-LF

## Key facts

- **NCT ID:** NCT01945710
- **Lead sponsor:** Eisai Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-11
- **Primary completion:** 2015-10
- **Final completion:** 2016-05-17
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2019-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01945710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01945710, "An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01945710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*